Referencias►
1.
Saint-John M, McNaughton L. Octacosanol ingestion and its effects on metabolic responses to submaximal cycle ergometry, reaction time and chest and grip strength
Int Clin Nutr Rev.
1986;6:81 - 87.
2.
Snider SR. Octacosanol in parkinsonism [letter].
Ann Neurol.
1984;16:723.
3.
Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.
Int J Clin Pharmacol Res. 2002;22:55 - 66.
4.
Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Int J Clin Pharmacol Res. 1999;19:117 - 127
5.
Crespo N, Alvarez R, Mas R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study.
Curr Ther Res. 1997;58:44 - 51.
6.
Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia.
Endocrinol Ginecológico. 2000;14:187 - 195.
7.
Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Int J Clin Pharmacol Res. 1999;19:105 - 116.
8.
Benitez M, Romero C, Mas R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia.
Curr Ther Res. 1997;58:859 - 867.
9.
Ortensi G, Gladstein J, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia.
Curr Ther Res. 1997;58:390 - 401.
10.
Alcocer L, Fernandez L, Campos E, et al. A comparative study of policosanol versus acipimox in patients with type II hypercholesterolemia.
Int J Tissue React. 1999;21:85 - 92.
11.
Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol.
Diabetes Care. 1995;19:393 - 397.
12.
Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
Clin Pharmacol Ther. 1999;65:439 - 447.
13.
Aneiros E, Mas R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia.
Curr Ther Res. 1995;56:176 - 182.
14.
Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study.
Curr Ther Res. 1995;56:819 - 828.
15.
Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia.
Curr Ther Res. 1996;57:691 - 699.
16.
Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol.
Diabetes Care. 1995;18:393 - 397.
17.
Aneiros E, Calderon B, Mas R, et al. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment.
Curr Ther Res. 1993;54:304 - 312.
18.
Castano G, Mas R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia.
Curr Ther Res. 1995;56:296 - 304.
19.
Batista J, Stusser R, Penichet M, et al. Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis.
Curr Ther Res. 1995;56:906 - 914.
20.
Pons P, Rodriguez M, Mas R, et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia.
Curr Ther Res. 1994;55:1084 - 1092.
21.
Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Int J Clin Pharm Res. 1994;14:27 - 33.
22.
Pons P, Mas R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia.
Curr Ther Res. 1992;52:507 - 513.
23.
Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
Angiología. 1999;50:123 - 130.
24.
Saint-John M, McNaughton L. Octacosanol ingestion and its effects on metabolic responses to submaximal cycle ergometry, reaction time and chest and grip strength.
Int Clin Nutr Rev. 1986;6:81 - 87.
25.
Snider SR. Octacosanol in parkinsonism.
Ann Neurol. 1984;16:723.
26.
Norris FH, Denys EH, Fallat RJ. Trial of octacosanol in amyotrophic lateral sclerosis.
Neurología. 1986;36:1263 - 1264.
27.
Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet.
Br J Nutr. 1997;77:923 - 932.
28.
Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol.
Cuidado de la Diabetes. 1995;18:393 - 397.
29.
Crespo N, Alvarez R, Mas R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study.
Curr Ther Res. 1997;58:44 - 51.
30.
Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia.
Endocrinol Ginecológico. 2000;14:187 - 195.
31.
Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol.
Diabetes Care. 1995;19:393 - 397.
32.
Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
Clin Pharmacol Ther. 1999;65:439 - 447.
33.
Aneiros E, Mas R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia
. Curr Ther Res . 1995;56:176 - 182.
34.
Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study.
Curr Ther Res. 1995;56:819 - 828.
35.
Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia.
Curr Ther Res. 1996;57:691 - 699.
36.
Aneiros E, Calderon B, Mas R, et al. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment.
Curr Ther Res. 1993;54:304 - 312.
37.
Castano G, Mas R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia.
Curr Ther Res. 1995;56:296 - 304.
38.
Batista J, Stusser R, Penichet M, et al. Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis.
Curr Ther Res. 1995;56:906 - 914.
39.
Pons P, Rodriguez M, Mas R, et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia.
Curr Ther Res. 1994;55:1084 - 1092.
40.
Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Int J Clin Pharm Res. 1994;14:27 - 33.
41.
Pons P, Mas R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia.
Curr Ther Res. 1992;52:507 - 513.
42.
Zardoya R, Tula L, Castano G, et al. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function.
Curr Ther Res.
1996;57:568 - 577.
43.
Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia.
Gynecol Endocrinol.
2000;14:187 - 195.
44.
Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
Clin Pharmacol Ther. 1999;65:439 - 447.
45.
Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Int J Clin Pharmacol Res.
1999;19:105 - 116.
46.
Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Int J Clin Pharmacol Res.
1999;19:117 - 127.
47.
Benitez M, Romero C, Mas R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia.
Curr Ther Res. 1997;58:859 - 867.
48.
Ortensi G, Gladstein J, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia.
Curr Ther Res. 1997;58:390 - 401.
49.
Alcocer L, Fernandez L, Campos E, et al. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
Int J Tissue React. 1999;21:85 - 92.
50.
Fernandez JC, Mas R, Castano G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women.
Clin Drug Invest. 2001;21:103 - 113.
51.
Castano G, Mas R, Fernandez JC, et al. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors.
Curr Ther Res.
2000;61:137 - 146.
52.
Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol.
Diabetes Care. 1995;18:393 - 397.
53.
Crespo N, Alvarez R, Mas R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study.
Curr Ther Res. 1997;58:44 - 51.
54.
Castano G, Mas Ferreiro R, Fernandez L, et al. A long-term study of policosanol in the treatment of intermittent claudication.
Angiology. 2001;52:115 - 125.
55.
Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
Angiology. 1999;50:123 - 130.
56.
Arruzazabala ML, Valdes S, Mas R, et al . Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers.
Pharmacol Res. 1996;34:181 - 185.
57.
Carbajal D, Arruzazabala ML, Valdes S, et al. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers.
Prostaglandins Leukot Essent Fatty Acids. 1998;58:61 - 64.
58.
Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers.
Pharmacol Res. 1997;36:293 - 297.
59.
Fernandez L, Mas R, Illnait J, et al. Policosanol: results of a postmarketing surveillance control on 27,879 patients.
Curr Ther Res. 1998;59:717 - 722.
60.
Rodriguez-Echenique C, Mesa R, Mas R, et al. Effects of policosanol chronically administered in male monkeys (Macaca arctoides).
Fd Chem Toxic. 1994;32:565 - 575.
61.
Mesa AR, Mas R, Noa M, et al. Toxicity of policosanol in beagle dogs: one-year study
. Toxicol Lett . 1994;73:81 - 90.
62.
Aleman CL, Mas R, Hernandez C, et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats.
Toxicol Lett. 1994;70:77 - 87.
63.
Rodriguez MD, Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit.
Teratog Carcinog Mutagen. 1994;14:107 - 113.
64.
Zardoya R, Tula L, Castano G, et al. Effects of policosanol on hypercholesterolemic abnormal serum biochemical indicators of hepatic function.
Curr Ther Res. 1996;57:568 - 577.
65.
Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia.
Curr Ther Res. 1996;57:691 - 699.
66.
Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Int J Clin Pharmacol Res.
1999;19:105 - 116.
67.
Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
Int J Tissue React.
1998;20:119 - 124.
68.
Arruzazabala ML, Valdes S, Mas R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers.
Pharmacol Res.
1996;34:181 - 185.
69.
Arruzazabala ML, Valdes S, Mas R, et al . Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers.
Pharmacol Res. 1997;36:293 - 297.
70.
Snider SR. Octacosanol in parkinsonism [letter].
Ann Neurol.
1984;16:723.
71.
Mirkin A., et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.
Int. J Clin Pharm Res
2001;21:31-34.
72.
Gamez R, eta l. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats.
J Med Food.
2001;4:57-65.
73.
Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.
Am Heart J.
2002;143:356 - 365.
74.
Castano G, Mas R, Fernandez JC, et al. Effects of policosanol on older patients with hypertension and type II hypercholesterolemia.
Drugs R D.
2002;3:159-172.
75.
Arruzazabala ML, Molina V, Mas R, et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients.
Clin Exp Pharmacol Physiol.
2002;29:891-897.
76.
Castano G, Mas R, Fernandez L, et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study.
Angiología. 2003;54:25 - 38.
